Corporate Overview

Alteris Therapeutics, Inc (formerly called Spliceomix, Inc) is focused on the discovery and development of therapeutics and vaccines against novel, proprietary cancer targets. Alteris has identified targets found only on cancer cells; normal cells do not express these targets. The Company’s first compound, ALT - 110 , is currently being tested in a Phase 1 clinical vaccine trial against one such target. In addition, Alteris has identified a second proprietary target, which is the focus of both a therapeutic and a vaccine drug discovery program. The Company expects to move a therapeutic monoclonal antibody product against this target to preclinical development by end of 2004. These initial targets have been implicated in a wide variety of cancers, including those of the breast, prostate, lung, ovary, and central nervous system. Using its proprietary RIAS discovery platform to identify and patent novel targets from cancer cells and tissues, the Company intends to create a robust pipeline of highly expressed tumor specific targets and develop therapeutics or vaccines against the most promising candidates.